Fig. 2From: BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301)Summary of standard (Arm A) and experimental (Arm B) treatment regimens (displays treatment administration in terms of nominal weeks, and not calendar weeks, and thus accommodates treatment delays)Back to article page
